Rafael Holdings Inc. (RFL) and Aduro BioTech Inc. (NASDAQ:ADRO) Comparing side by side

We will be contrasting the differences between Rafael Holdings Inc. (NYSEAMERICAN:RFL) and Aduro BioTech Inc. (NASDAQ:ADRO) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rafael Holdings Inc. 4.46M 41.02 3.28M -0.03 0.00
Aduro BioTech Inc. 15.09M 21.77 95.36M -1.17 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Rafael Holdings Inc. and Aduro BioTech Inc.

Profitability

Table 2 represents Rafael Holdings Inc. (NYSEAMERICAN:RFL) and Aduro BioTech Inc. (NASDAQ:ADRO)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Rafael Holdings Inc. -73.54% -3.1% -2.6%
Aduro BioTech Inc. -631.94% -57.2% -24.6%

Liquidity

Rafael Holdings Inc.’s Current Ratio is 46.1 while its Quick Ratio is 46.1. On the competitive side is, Aduro BioTech Inc. which has a 9.3 Current Ratio and a 9.3 Quick Ratio. Rafael Holdings Inc. is better positioned to pay off short and long-term obligations compared to Aduro BioTech Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Rafael Holdings Inc. and Aduro BioTech Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Rafael Holdings Inc. 0 0 0 0.00
Aduro BioTech Inc. 0 0 2 3.00

Competitively the consensus target price of Aduro BioTech Inc. is $8.5, which is potential 106.31% upside.

Insider & Institutional Ownership

Roughly 39.4% of Rafael Holdings Inc. shares are held by institutional investors while 50.7% of Aduro BioTech Inc. are owned by institutional investors. Insiders held 1.3% of Rafael Holdings Inc. shares. On the other hand, insiders held about 1.4% of Aduro BioTech Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rafael Holdings Inc. -0.31% 4.22% 96.21% 70.78% 0% 102.65%
Aduro BioTech Inc. -0.24% 40.6% 64.96% -33.49% -31.87% 58.71%

For the past year Rafael Holdings Inc. has stronger performance than Aduro BioTech Inc.

Summary

Rafael Holdings Inc. beats Aduro BioTech Inc. on 9 of the 11 factors.

Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.